

# CITATION REPORT

List of articles citing

Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays

DOI: 10.1186/1477-9560-12-24  
Thrombosis Journal, 2014, 12, 24.

**Source:** <https://exaly.com/paper-pdf/58434362/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
40	New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. <i>Therapeutics and Clinical Risk Management</i> , <b>2015</b> , 11, 967-77	2.9	227
39	Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug Concentrations. <i>BioMed Research International</i> , <b>2015</b> , 2015, 345138	3	30
38	Does the Russell Viper Venom time test provide a rapid estimation of the intensity of oral anticoagulation? A cohort study. <i>Thrombosis Research</i> , <b>2015</b> , 135, 852-60	8.2	23
37	Stroke prevention in atrial fibrillation: evidence from real-life studies: Table 1. <i>European Heart Journal Supplements</i> , <b>2015</b> , 17, D42-D52	1.5	4
36	Point-of-Care Testing of Coagulation in Patients Treated With Non-Vitamin K Antagonist Oral Anticoagulants. <i>Stroke</i> , <b>2015</b> , 46, 2741-7	6.7	53
35	Edoxaban: Impact on routine and specific coagulation assays. A practical laboratory guide. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 115, 368-81	7	50
34	Interference of anticoagulants on coagulation testing. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2016</b> , 54, e207-10	5.9	
33	Mass spectrometry in the therapeutic drug monitoring of direct oral anticoagulants. Useful or useless?. <i>TrAC - Trends in Analytical Chemistry</i> , <b>2016</b> , 84, 41-50	14.6	12
32	Direct oral anticoagulants and the bleeding patient. <i>Cmaj</i> , <b>2016</b> , 188, 215	3.5	0
31	Practical Considerations for the Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2017</b> , 23, 5-19	3.3	9
30	Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants. <i>Critical Care</i> , <b>2017</b> , 21, 32	10.8	41
29	Direct acting oral anticoagulant: Bench to bedside. <i>Medical Journal Armed Forces India</i> , <b>2017</b> , 73, 274-281	1.9	
28	Influence of apixaban on commonly used coagulation assays: results from the Belgian national External Quality Assessment Scheme. <i>International Journal of Laboratory Hematology</i> , <b>2017</b> , 39, 402-408	2.5	17
27	The Anticoagulated trauma patient in the age of the direct oral anticoagulants: a Canadian perspective. <i>Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine</i> , <b>2017</b> , 25, 76	3.6	19
26	Apixaban pharmacodynamic activity in umbilical cord, paediatric, and adult plasma. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 1518-1527	7	6
25	European guidelines on perioperative venous thromboembolism prophylaxis: Patients with preexisting coagulation disorders and after severe perioperative bleeding. <i>European Journal of Anaesthesiology</i> , <b>2018</b> , 35, 96-107	2.3	7
24	Laboratory measures of coagulation among trauma patients on NOAs: results of the AAST-MIT. <i>Trauma Surgery and Acute Care Open</i> , <b>2018</b> , 3, e000231	2.4	9

23	Limitations of Specific Coagulation Tests for Direct Oral Anticoagulants: A Critical Analysis. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7, e009807	6	29
22	Time in the Therapeutic Range for Assessing Anticoagulation Quality in Patients Receiving Continuous Unfractionated Heparin. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2018</b> , 24, 178S-181S	3.3	5
21	An Overview of the Anticoagulant Drugs Used in Routine Clinical Practice. <b>2018</b> ,		2
20	Rivaroxaban dose adjustment using thrombin generation in severe congenital protein C deficiency and warfarin-induced skin necrosis. <i>Blood Advances</i> , <b>2018</b> , 2, 142-145	7.8	14
19	Intravenous thrombolysis in stroke patients taking novel oral anticoagulants: experience with the low-dose 0.6 mg/kg of recombinant tissue-type plasminogen activator. Case reports. <i>Journal of the Neurological Sciences</i> , <b>2018</b> , 393, 24-26	3.2	2
18	The rivaroxaban-adjusted normalized ratio: use of the prothrombin time to monitor the therapeutic effect of rivaroxaban. <i>British Journal of Biomedical Science</i> , <b>2019</b> , 76, 122-128	1.6	2
17	Advances in monitoring anticoagulant therapy. <i>Advances in Clinical Chemistry</i> , <b>2019</b> , 90, 197-213	5.8	1
16	Development of new methodologies for the chromogenic estimation of betrixaban concentrations in plasma. <i>International Journal of Laboratory Hematology</i> , <b>2019</b> , 41, 250-261	2.5	7
15	Diagnostic performance of coagulation indices for direct oral anticoagulant concentration. <i>Thrombosis Research</i> , <b>2020</b> , 195, 171-179	8.2	2
14	Comparison of outcomes in non-head injured trauma patients using pre-injury warfarin or direct oral anticoagulant therapy. <i>Injury</i> , <b>2020</b> , 51, 2546-2552	2.5	1
13	Point-of-Care Hematology. <b>2020</b> , 123-138		
12	2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. <i>Thrombosis and Haemostasis</i> , <b>2021</b> , 121, 1008-1020 <sup>21</sup>	7	
11	Drugs in phase I and II clinical development for the prevention of stroke in patients with atrial fibrillation. <i>Expert Opinion on Investigational Drugs</i> , <b>2021</b> , 30, 1057-1069	5.9	1
10	Review of coagulation preanalytical variables with update on the effect of direct oral anticoagulants. <i>International Journal of Laboratory Hematology</i> , <b>2021</b> , 43 Suppl 1, 109-116	2.5	2
9	Newer Oral Anticoagulants: Stroke Prevention and Pitfalls. <i>Open Cardiovascular Medicine Journal</i> , <b>2016</b> , 10, 94-104	0.7	6
8	Efficacy and safety of non-vitamin K antagonist oral anticoagulants post-kidney transplantation. <i>World Journal of Transplantation</i> , <b>2019</b> , 9, 134-144	2.3	10
7	Update on laboratory testing and hemostasis assessment in patients receiving direct oral anticoagulants (DOACs). <i>Thrombosis Update</i> , <b>2021</b> , 5, 100084	0.9	0
6	Determination of anticoagulant activity of direct oral anticoagulants: the current state of knowledge and a single center experience. <b>2017</b> , 53, 161-168		1

5	Direct Oral Anticoagulants and their Clinical Management. <i>Hematology &amp; Transfusion International Journal</i> , <b>2017</b> , 5,	1
4	Performance Evaluation of the CS-5100 Coagulation Analyzer for Special Coagulation Parameters. <i>Laboratory Medicine Online</i> , <b>2020</b> , 10, 25	0.2
3	Comparison of analytical performances between clot waveform analysis and FibWave in edoxaban-treated patients and healthy controls. <b>2022</b> , 6,	0
2	Minimisation of Bleeding Risks Due to Direct Oral Anticoagulants. 78-90	0
1	Evaluation of CoaguChek <sup>®</sup> Pro II coagulation testing device performance to assess direct oral anticoagulant action. The DOAC-CHECK study. <b>2022</b> , 1,	0